Bioaffinity Technologies Inc (BIAF)

$2.61 -0.17 (-6.12%)
Market Cap 2.57M
Revenue (ttm) 9.36M
Net Income (ttm) -9.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -96.58%
Debt to Equity Ratio -0.04
Volume 569,100
Avg Vol 2,306,340
Day's Range N/A - N/A
Shares Out 985,000.00
Stochastic %K 1%
Beta 2.32
Analysts Hold
Price Target $6.00

Company Profile

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, incl...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 210 698 5334
Address:
3300 Nacogdoches Road, Suite 216, San Antonio, United States
Hotresearchsgoldenage
Hotresearchsgoldenage Oct. 5 at 1:07 AM
$BIAF the test results were phenomenal! The offering is what caused the dip to the 2.50ish mark that shares were sold . Real Support now and expect a bounce. ! A buyout is probable with huge upside potential and immediate squeeze with news !
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 4 at 5:56 PM
Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve! $BIAF $TXG $NRGV $DEO
0 · Reply
TheRealRazingCane
TheRealRazingCane Oct. 3 at 8:19 PM
$BIAF Anyone familiar with Dante?? "Abbandono ogni esperanza voi che entrada".
1 · Reply
TitusPullo1964
TitusPullo1964 Oct. 3 at 8:19 PM
$BIAF As soon as more positive news comes in, she'll take off. Just be patient. Her new test for the early detection of lung cancer and patent is worth its weight in gold.
1 · Reply
Hotresearchsgoldenage
Hotresearchsgoldenage Oct. 3 at 8:05 PM
$BIAF low volume ! Retail capitulation! Wasn’t tutes !
0 · Reply
TitusPullo1964
TitusPullo1964 Oct. 3 at 6:33 PM
$BIAF Should be higher after such good news with the patent, after the split at around $3, I remember? It went up briefly after the positive news, into the $5-6 range. Then it immediately went back down to that range. Hmm.....? In my opinion, it really has potential and should be higher. I'm in.
0 · Reply
Hotresearchsgoldenage
Hotresearchsgoldenage Oct. 3 at 6:31 PM
$BIAF only 460k volume traded and 10 million average! Retail folding ! I’m Buying !
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 5:33 PM
$VOR $BIAF $ECDA $ATHA Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
LouKojak
LouKojak Oct. 3 at 5:24 PM
$BIAF big price drop on low volume. Maybe I'm interested 🤑
1 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 5:04 PM
$BIAF $ILMN $ARCT $URG Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
Latest News on BIAF
WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m

Sep 30, 2025, 12:44 PM EDT - 4 days ago

WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m

bioAffinity Technologies Announces Closing of $4.8 Million Public Offering

Sep 30, 2025, 12:15 PM EDT - 4 days ago

bioAffinity Technologies Announces Closing of $4.8 Million Public Offering

WallachBeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8m

Sep 29, 2025, 5:59 PM EDT - 5 days ago

WallachBeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8m

bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering

Sep 29, 2025, 3:51 PM EDT - 5 days ago

bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering

bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung

Sep 26, 2025, 8:00 AM EDT - 8 days ago

bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung

bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025

Sep 17, 2025, 8:15 AM EDT - 17 days ago

bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025

Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules

Sep 9, 2025, 8:00 AM EDT - 25 days ago

Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules

bioAffinity Technologies Appoints New Members to Board of Directors

Aug 18, 2025, 8:00 AM EDT - 6 weeks ago

bioAffinity Technologies Appoints New Members to Board of Directors

bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

Aug 14, 2025, 4:15 PM EDT - 7 weeks ago

bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

bioAffinity Technologies Reports Second Quarter 2025 Results

Aug 14, 2025, 8:00 AM EDT - 7 weeks ago

bioAffinity Technologies Reports Second Quarter 2025 Results

bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

Aug 13, 2025, 9:25 AM EDT - 7 weeks ago

bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales

Aug 13, 2025, 8:00 AM EDT - 7 weeks ago

bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales

Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results

Jul 29, 2025, 8:00 AM EDT - 2 months ago

Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results

Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic

Jul 22, 2025, 9:00 AM EDT - 2 months ago

Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic

bioAffinity Technologies Announces Notification of China Patent Award for Company's Noninvasive Lung Cancer Diagnostic

Jul 15, 2025, 9:00 AM EDT - 2 months ago

bioAffinity Technologies Announces Notification of China Patent Award for Company's Noninvasive Lung Cancer Diagnostic

bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference

Jun 26, 2025, 9:00 AM EDT - 3 months ago

bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference

bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy

Jun 24, 2025, 9:00 AM EDT - 3 months ago

bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy

bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board

Jun 11, 2025, 9:00 AM EDT - 4 months ago

bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board

bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics

May 28, 2025, 9:00 AM EDT - 4 months ago

bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics

bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer

May 20, 2025, 9:00 AM EDT - 4 months ago

bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer

bioAffinity Technologies Reports First Quarter 2025 Results

May 15, 2025, 8:30 AM EDT - 5 months ago

bioAffinity Technologies Reports First Quarter 2025 Results

Independent White Paper Highlights Real-World Impact of bioAffinity Technologies' CyPath® Lung in Diagnosing Early-Stage Lung Cancer

May 8, 2025, 9:00 AM EDT - 5 months ago

Independent White Paper Highlights Real-World Impact of bioAffinity Technologies' CyPath® Lung in Diagnosing Early-Stage Lung Cancer

WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering

May 7, 2025, 1:15 PM EDT - 5 months ago

WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering

bioAffinity Technologies Announces Closing of $3.25 Million Offering

May 7, 2025, 1:00 PM EDT - 5 months ago

bioAffinity Technologies Announces Closing of $3.25 Million Offering

WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering

May 6, 2025, 10:30 AM EDT - 5 months ago

WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering

bioAffinity Technologies Announces Pricing of $3.25 Million Offering

May 6, 2025, 9:25 AM EDT - 5 months ago

bioAffinity Technologies Announces Pricing of $3.25 Million Offering

bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

Apr 17, 2025, 9:15 AM EDT - 6 months ago

bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024

Mar 31, 2025, 9:28 AM EDT - 6 months ago

bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024

Case Study: bioAffinity Technologies' CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer

Mar 26, 2025, 9:00 AM EDT - 6 months ago

Case Study: bioAffinity Technologies' CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer

Case Study: bioAffinity Technologies' Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence

Mar 19, 2025, 9:00 AM EDT - 7 months ago

Case Study: bioAffinity Technologies' Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence

Physicians' Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer

Mar 13, 2025, 9:00 AM EDT - 7 months ago

Physicians' Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer

bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth

Mar 6, 2025, 8:00 AM EST - 7 months ago

bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth

WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

Feb 26, 2025, 12:10 PM EST - 7 months ago

WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

Feb 26, 2025, 11:30 AM EST - 7 months ago

bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

Feb 25, 2025, 11:05 AM EST - 7 months ago

WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

Feb 25, 2025, 9:58 AM EST - 7 months ago

bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic

Jan 22, 2025, 8:00 AM EST - 9 months ago

bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic

bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung

Jan 13, 2025, 8:00 AM EST - 9 months ago

bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jan 10, 2025, 9:00 AM EST - 9 months ago

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ENLV

Join bioAffinity Technologies' Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19

Dec 17, 2024, 8:00 AM EST - 10 months ago

Join bioAffinity Technologies' Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19

bioAffinity Technologies Set for Continued Expansion in 2025

Dec 12, 2024, 8:00 AM EST - 10 months ago

bioAffinity Technologies Set for Continued Expansion in 2025

bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024

Nov 14, 2024, 8:00 AM EST - 11 months ago

bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024

bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development

Nov 4, 2024, 8:00 AM EST - 11 months ago

bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development

bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung

Oct 30, 2024, 8:00 AM EDT - 1 year ago

bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung

WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement

Oct 21, 2024, 11:39 AM EDT - 1 year ago

WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement

bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement

Oct 21, 2024, 10:45 AM EDT - 1 year ago

bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement

WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement

Oct 18, 2024, 2:57 PM EDT - 1 year ago

WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement

bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement

Oct 18, 2024, 12:45 PM EDT - 1 year ago

bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement

bioAffinity's CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines

Oct 16, 2024, 8:00 AM EDT - 1 year ago

bioAffinity's CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines

bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer

Oct 10, 2024, 8:00 AM EDT - 1 year ago

bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer

Hotresearchsgoldenage
Hotresearchsgoldenage Oct. 5 at 1:07 AM
$BIAF the test results were phenomenal! The offering is what caused the dip to the 2.50ish mark that shares were sold . Real Support now and expect a bounce. ! A buyout is probable with huge upside potential and immediate squeeze with news !
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 4 at 5:56 PM
Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve! $BIAF $TXG $NRGV $DEO
0 · Reply
TheRealRazingCane
TheRealRazingCane Oct. 3 at 8:19 PM
$BIAF Anyone familiar with Dante?? "Abbandono ogni esperanza voi che entrada".
1 · Reply
TitusPullo1964
TitusPullo1964 Oct. 3 at 8:19 PM
$BIAF As soon as more positive news comes in, she'll take off. Just be patient. Her new test for the early detection of lung cancer and patent is worth its weight in gold.
1 · Reply
Hotresearchsgoldenage
Hotresearchsgoldenage Oct. 3 at 8:05 PM
$BIAF low volume ! Retail capitulation! Wasn’t tutes !
0 · Reply
TitusPullo1964
TitusPullo1964 Oct. 3 at 6:33 PM
$BIAF Should be higher after such good news with the patent, after the split at around $3, I remember? It went up briefly after the positive news, into the $5-6 range. Then it immediately went back down to that range. Hmm.....? In my opinion, it really has potential and should be higher. I'm in.
0 · Reply
Hotresearchsgoldenage
Hotresearchsgoldenage Oct. 3 at 6:31 PM
$BIAF only 460k volume traded and 10 million average! Retail folding ! I’m Buying !
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 5:33 PM
$VOR $BIAF $ECDA $ATHA Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
LouKojak
LouKojak Oct. 3 at 5:24 PM
$BIAF big price drop on low volume. Maybe I'm interested 🤑
1 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 5:04 PM
$BIAF $ILMN $ARCT $URG Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
geumrivale
geumrivale Oct. 3 at 3:42 PM
$BIAF diluation started
0 · Reply
sem18
sem18 Oct. 3 at 3:11 PM
$BIAF Friendד. Is it worth buying?
1 · Reply
Khaled43
Khaled43 Oct. 3 at 2:19 PM
$BIAF $ECDA $SQNS $VOR Ecda
0 · Reply
Logic102
Logic102 Oct. 3 at 3:20 AM
$BIAF Buying when the herd has left it for dead and you see life. In short, always buy low and sell high. Look for Asymmetric Risk Reward Opportunities.
1 · Reply
HouseOfTheDragons
HouseOfTheDragons Oct. 3 at 2:35 AM
Looks like volume & momentum could be shifting in to ASTC! Tiny float getting a lot of attention and could explode upwards on volume. Watchers on ASTC are growing very fast and it could be the potential top runner for this week! Starting its 300% run - keep it on watch! Also watching for breakout: $BGXX $BIAF $BIOR $BLBX !"
0 · Reply
twighttrades1
twighttrades1 Oct. 3 at 1:45 AM
$BIAF - reverse was rone, the offering followed, shares out are still so minimal that this is a buy here where we are - this reacts on mews - have to be quick to trade out if it… story might change with this frw shares now- bought more tday and will add if below 2.6
0 · Reply
MoonCowBoy
MoonCowBoy Oct. 2 at 11:45 PM
$VOR $BIAF $ECDA $SQNS !!
0 · Reply
Ashsol7
Ashsol7 Oct. 2 at 10:58 PM
$BIAF 867% barrow fee 💵💵💵💵 shorts are finished 🤲🏼
0 · Reply
Ashsol7
Ashsol7 Oct. 2 at 9:05 PM
$BIAF
1 · Reply
TheWolfOfCalgary
TheWolfOfCalgary Oct. 2 at 6:20 PM
$BIAF guys, help me plan an exit strategy. I’m at a definitive loss right now. Down -58% this money I need it for a car now, how do I get out and how long should I hold my breath for ? Anyone whose been dealing with penny stocks for a while, if you can advice me, I would be grateful.
3 · Reply
1Spartantrade1
1Spartantrade1 Oct. 2 at 6:17 PM
Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $BINI $VOR $BIAF $ECDA 🔥
0 · Reply
Logic102
Logic102 Oct. 2 at 4:54 PM
$IVDA $BIAF my two beaten to Hell and back nanocap picks in recent weeks before any major swings just based on Asymmetric Risk/Reward with actual revenue and game changing products. Nothing has changed in that assessment and BIAF is even more attractive now after being beaten down all the more. Patience pays.
1 · Reply